title: ABO-Incompatible Living Kidney Transplant Recipients from Spousal Donors Receiving Rituximab.
abstract: BACKGROUND
  We summarized our experience with ABO-incompatible living kidney transplant recipients from spousal donors receiving rituximab.
  
  
  METHODS
  Between June 2006 and December 2014, 82 patients with end-stage renal disease underwent living donor kidney transplantation at Osaka City University Hospital, of which 23 cases were ABO-incompatible transplantation between spouses with rituximab induction. We analyzed these recipients, focusing on their immunosuppressive protocols, frequency of acute rejections, and patient/graft survivals.
  
  
  RESULTS
  Patient and graft survival rates were 100%. The incidence of acute cellular rejection (ACR) was 30.4%. One patient experienced antibody-mediated rejection (AMR) and intractable ACR, 2 had AMR, and 2 had intractable ACR episodes that were treated using thymoglobulin.
  
  
  CONCLUSIONS
  This study demonstrated that ABO-incompatible kidney transplantation between spouses using rituximab is a radical but effective treatment for end-stage renal disease. However, this procedure could be immunologically high risk due to ABO-incompatibility and poor histocompatibility.
authors.affiliation: Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: Junji
authors.initials: J
authors.lastname: Uchida
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Iwai
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kabei
authors.forename: Shunji
authors.initials: S
authors.lastname: Nishide
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamasaki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kuwabara
authors.forename: Toshihide
authors.initials: T
authors.lastname: Naganuma
authors.forename: Norihiko
authors.initials: N
authors.lastname: Kumada
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatanti
mesh_terms: D000017:ABO Blood-Group System; D001787:Blood Group Incompatibility; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents; D016030:Kidney Transplantation; D019520:Living Donors; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents; D000069283:Rituximab